NewcelX Appoints Dr. Julien Boisdron, Swiss Big Pharma Leader, to Its Scientific Advisory Board

NewcelX Ltd. (NASDAQ: NCEL), a biotechnology company focused on developing cell‑based and small‑molecule therapies for neurodegenerative and metabolic diseases, has announced the appointment of Dr. Julien Boisdron, MD, to its Scientific Advisory Board (SAB). Dr. Boisdron, a recognized expert in diabetes care with more than two decades of experience in global pharmaceutical leadership, brings deep expertise from his role as Chief Medical Officer at a major Swiss multinational pharma company. At NewcelX, Dr. Boisdron will provide strategic guidance for the company’s lead therapeutic program, IsletRx — a stem‑cell‑derived islet cell therapy aimed at insulin‑dependent Type 1 Diabetes, NewcelX’s primary clinical focus. He will advise on translational strategy, clinical program development, patient adoption, health system integration, and global commercialization planning as the program advances toward clinical trials. In his appointment statement, Dr. Boisdron expressed honor at joining NewcelX’s SAB and collaborating to advance next‑generation diabetes therapies. Company leaders highlighted that his extensive background in diabetes innovation, clinical strategy, and worldwide healthcare systems strengthens NewcelX’s leadership in metabolic and regenerative medicine. #NewcelX #DiabetesInnovation #BiotechLeadership #IsletRx #SlimScan #GrowthStocks #CANSLIM